Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer R&D Reshuffling Deals Out Pharmacia’s Investment In Sugen

Executive Summary

Pfizer will cease investment in the biotech company Sugen as part of a reorganization of Pfizer/Pharmacia's combined R&D facilities

You may also be interested in...

Deals Of The Week: Value Surprise!

Sometimes the value of an asset is buried under serial acquisitions and doesn’t come to light for decades.. Also deal news from Janssen/GSK, Takeda/Immunomedics, Quintiles/Muscular Dystrophy Association, Vivus/Auxilium, Lilly/HMP, and Novartis/Immunogen

Pfizer Message To Michigan: Access, Not Taxes, Will Influence Employment

Pfizer's decision about the future of the former Upjohn campus in Michigan provides an opportunity for the company to renew its push for changes to the state's Medicaid program

Pfizer/Pharmacia Clears FTC: Viagra Patent Strategy, HRT Safety Are Factors

Pfizer's patent defense strategy for Viagra is one reason the Federal Trade Commission is requiring the divestiture of Phase II erectile dysfunction disorder agents as a condition of the Pfizer/Pharmacia merger

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts